Future Price to Earnings: Relmada Corp (RLMD)
Relmada Therapeutics (RLMD) relies on the validation of resmelmetan and a potential alliance with industry behemoths. The absence of sales makes the growth of testing costs linear. The company's forward P/E ratio visualizes these processes, where the value of 0.00 characterizes this level of revenue valuation. Meanwhile, the business is implementing energy-efficient technologies to minimize the environmental footprint of its laboratories.
Relmada Corp (RLMD) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Total Debt to Capital Relmada Therapeutics|RLMD - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Relmada Therapeutics|RLMD - Company Aggregate Debts|Debt to Book Value Relmada Therapeutics Inc|RLMD - Company Long-Term Loans and Borrowings|Company Current Liabilities Relmada Therapeutics|Quick Ratio relmada.com
- company profitability and valuation multiples indicators:
RLMD - Final Profit|Projected Future Earnings Relmada Therapeutics|RLMD - Market Cap to Earnings|Future Price to Earnings Relmada|RLMD - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Relmada Therapeutics Inc|RLMD - Operating profit EBITDA|Earnings per share for the last twelve months Relmada Therapeutics|RLMD - Earnings per one share for the last 12 months|Quarterly EPS earnings growth relmada.com|RLMD - Earnings per share growth rate in current year|Expected earnings per share growth for next year Relmada Therapeutics
Comprehensive company analysis:Relmada Therapeutics, Inc. RLMD
Relmada Therapeutics (RLMD) possesses a critical dependency on the success of a single antidepressant, rendering its market capitalization extremely sensitive to clinical trial results. By analyzing the company's forward P/E chart, an investor assesses the ratio of current share price to projected earnings, determining whether market expectations justify the risks of a single-product model and identifying the boundary between the asset's overvaluation and undervaluation.
Direct competitors
Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Future Price to Earnings Regencell RGC|Axsome Corp - Future Price to Earnings|ACAD - Future Price to Earnings|xenon-pharma.com (XENE) - Projected Price to Earnings|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Forward P/E Multiple|CPRX (Catalyst Pharmaceuticals Inc) - Forward P/E Multiple|Price to Future Earnings Ratio DNLI (Denali Corp)|Forward P/E Multiple HRMY|Forward P/E Multiple biohavenpharma.com (BHVN)|Amylyx Pharmaceuticals, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple TRVI|PRAX: Projected Price to Earnings|Anavex Life Sciences Corp - Market Cap to Future Earnings Ratio|CBLL: Forward P/E Multiple|Prothena - Future Price to Earnings Multiple|ALEC (Alector Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio Annexon Biosciences ANNX|Future Price to Earnings Omeros Corporation (OMER)|NGNE (Neurogene Therapeutics) - Future Price to Earnings Multiple|Forward P/E Multiple ACIU (AC Immune)|Forward P/E Multiple voyagertherapeutics.com VYGR|NMRA - Future Price to Earnings|Price to Expected Earnings Ratio SCLX|TVGN: Forward P/E Multiple|Projected Price to Earnings Ratio Alpha Cognition Inc. (ACOG)|Projected Price to Earnings CGTX|Forward P/E Multiple inhibikase.com|Projected Price to Earnings SAVA (Cassava Sciences)|Market Cap to Future Earnings Ratio ASRT|Forward P/E Multiple COYA (Coya Therapeutics)|Market Cap to Projected Earnings VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Forward P/E Multiple|acumenpharm.com (ABOS) - Projected Price to Earnings|CervoMed (CRVO) - Future Price to Earnings|ATHE - Market Cap to Projected Earnings|Future Price to Earnings Clene Inc|PEPG: Future Price to Earnings Multiple|Future Price to Earnings Jupiter Neurosciences Inc (JUNS)|Future Price to Earnings ANVS (annovisbio.com)|Future Price to Earnings Grace Therapeutics GRCE|AIFF - Projected Price to Earnings|ANEW Medical, Inc. - Forward P/E Multiple|NRSN (NeuroSense Therapeutics) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|Price to Future Earnings Ratio MTVA|NRXS (NeurAxis) - Forward P/E Multiple|Projected Price to Earnings Ratio Helius Medical Technologies Inc. HSDT|Projected Price to Earnings PASG (Passage Bio, Inc.)|Forward P/E Multiple bionomics.com.au (NEUP)|Future Price to Earnings Minerva Neurosciences NERV|Future Price to Earnings Multiple ATHA|ADXN - Future Price to Earnings|Projected Price to Earnings Ratio Alzamend Neuro, Inc.|cyclerion.com (CYCN) - Future Price to Earnings|Protagenic Therapeutics, Inc. - Future Price to Earnings Multiple|KTTA (Pasithea Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Cortigent Medical CRGT|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|Future Price to Earnings BCLI (Brainstorm Cell Therapeutics Inc.)|Future Price to Earnings Cara Therapeutics, Inc CARA|CHRO - Projected Price to Earnings|Eliem - Forward P/E Multiple|ITCI - Forward P/E Multiple|LBPH: Forward P/E Multiple|Price to Future Earnings Ratio MRNS|NKGN (NKGen) - Forward P/E Multiple|Forward P/E Multiple NeuroBo Pharma|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|SNPX (synaptogen.com) - Future Price to Earnings Multiple|Trevena - Projected Price to Earnings|Market Cap to Future Earnings Ratio VIGL (Vigil Neuroscience Inc.)|Anew Medical - Forward P/E Multiple|Future Price to Earnings Multiple CERE (Cerevel Corp)
